Blood cancer discovery · 2026
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xing Ruixian, Yang Apeng, Huang Juan, Wang Liang, Guo Wei, Cui Qu, Tang Xiaoqiong, Ma Yuanyuan, Hu Kai, He Tianheng, Wu Danyang, Deng Xiaofang, Zhang Yajing, Zhong Kaili, Liu Yang, Guo Yixian, Wang Ying, Long Chan, Wu Chongyang, Lu Xin, Li Fengmin, Bai Jiefei, Qian Jun, Sun Xuefei, Huang Wenrong, Zhou Hui, Zhang Huilai, Bai Ou, Huang Xiaobing, Zeng Zhiyong, Fu Lin
Аннотация
Relapsed or refractory CNS lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive R/R CNSL patients (median age 59 years; 53 PCNSL, 31 SCNSL) to evaluate efficacy and safety profiles of glofitamab therapy. With a median of 2.5 prior lines of therapy, the objective response rates (ORR) and complete response rates (CRR) for PCNSL were 88% (CRR 59%) with glofitamab monotherapy (n=32) and 100% (CRR 81%) with combination therapy (n=21), respectively; for SCNSL, ORR and CRR were 88% (CRR 75%) with glofitamab monotherapy (n=8) and 91% (CRR 65%) with combination therapy (n=23). At 14.7 months follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grade 1-2) of patients, and ICANS in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for R/R CNSL patients.